VivoSim Labs (FRA:4OR) Accounts Payable & Accrued Expense: €1.37 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4OR VivoSim Labs Inc FRA:4OR
33 GF Score
Price €3.49
GF Value €15.55
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs Accounts Payable & Accrued Expense?

VivoSim Labs FRA:4OR 33 Accounts Payable & Accrued Expense is €1.37 Mil as of Mar. 2026. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €15.55. The stock has 6 warning signs investors should review.

VivoSim Labs's quarterly accounts payable & accrued expense increased from Sep. 2025 (€0.96 Mil) to Dec. 2025 (€1.07 Mil) and increased from Dec. 2025 (€1.07 Mil) to Mar. 2026 (€1.37 Mil).

VivoSim Labs's annual accounts payable & accrued expense increased from Mar. 2024 (€0.75 Mil) to Mar. 2025 (€2.05 Mil) but then declined from Mar. 2025 (€2.05 Mil) to Mar. 2026 (€1.37 Mil).

VivoSim Labs Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Accounts Payable & Accrued Expense Chart

VivoSim Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 2.40 0.75 2.05 1.37

VivoSim Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.05 1.08 0.96 1.07 1.37
FRA:4OR
33GF Score
VivoSim Labs Inc FRA:4OR
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of €1.37 Mil mean?
VivoSim Labs (FRA:4OR) has a Accounts Payable & Accrued Expense of €1.37 Mil as of Mar. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Accounts Payable & Accrued Expense too high?
VivoSim Labs' current Accounts Payable & Accrued Expense is €1.37 Mil. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Accounts Payable & Accrued Expense compare to MTNB and HEPA?
VivoSim Labs' Accounts Payable & Accrued Expense of €1.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Accounts Payable & Accrued Expense is €1.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Accounts Payable & Accrued Expense of €1.37 Mil. The stock's GF Value™ is €15.55, compared to a current price of €3.49 — trading 77.5% below its estimated fair value. The current Accounts Payable & Accrued Expense is €1.37 Mil. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Accounts Payable & Accrued Expense is €1.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 77.5% below its estimated GF Value™ of €15.55.

Key valuation signals for FRA:4OR:

  • Accounts Payable & Accrued Expense: €1.37 Mil
  • GF Value™: €15.55 vs. price of €3.49 (77.5% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score

Get the complete analysis for FRA:4OR

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€15.55
GF Value